Related Experiment Video

Updated: Apr 26, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

The use of sunitinib in renal cell carcinoma: where are we now?

Anna M Czarnecka1, Cezary Szczylik, Brian Rini

  • 1Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Warsaw, Poland.

Expert Review of Anticancer Therapy
|July 29, 2014
PubMed

Insights

Sunitinib malate improves progression-free survival in metastatic renal cell carcinoma (mRCC) patients compared to IFN-α. This targeted therapy demonstrates efficacy across various patient subgroups and is considered a gold standard treatment for mRCC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sunitinib malate is a multi-targeted protein tyrosine kinase inhibitor with demonstrated antitumor and antiangiogenic properties.
  • Metastatic renal cell carcinoma (mRCC) is a significant challenge in cancer treatment, necessitating effective therapeutic strategies.

Purpose of the Study:

  • To evaluate the efficacy of sunitinib malate compared to interferon-alfa (IFN-α) in treatment-naive patients with mRCC.
  • To assess the antitumor activity of sunitinib in a broader population of RCC patients, including those with refractory disease or specific metastatic characteristics.

Main Methods:

  • A randomized Phase III clinical trial comparing sunitinib malate to IFN-α in treatment-naive mRCC patients.
  • Analysis of efficacy in unselected RCC patient cohorts, including those with non-clear cell histology brain metastases and poor performance status.

Main Results:

  • Sunitinib malate significantly improved progression-free survival compared to IFN-α in treatment-naive mRCC patients.
  • Sunitinib demonstrated antitumor activity in various RCC patient groups, including those refractory to prior treatments.
  • Hypertension and other toxicities were observed, with potential utility as biomarkers for clinical outcomes.

Conclusions:

  • Sunitinib malate is a highly effective treatment for metastatic renal cell carcinoma, offering significant survival benefits.
  • The drug shows broad applicability across diverse RCC patient profiles, solidifying its role as a gold standard therapy.
  • Monitoring specific toxicities may aid in predicting patient response to sunitinib treatment.
Keywords:
SU11248VEGFbiomarkerclear cell cancerrenal cell cancersunitinibtyrosine kinase

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

16.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
1.2K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
1.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K